Q1 Earnings Estimate for IOVA Issued By HC Wainwright

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Iovance Biotherapeutics in a research note issued on Friday, February 28th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.23) for the quarter. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q4 2025 earnings at ($0.13) EPS.

Several other research firms have also recently issued reports on IOVA. Chardan Capital cut their target price on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Monday. Truist Financial cut their price objective on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating for the company in a research report on Monday. The Goldman Sachs Group decreased their target price on shares of Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday. Piper Sandler dropped their price target on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating for the company in a research report on Friday. Finally, Robert W. Baird decreased their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.25.

Iovance Biotherapeutics Stock Down 4.7 %

NASDAQ IOVA opened at $4.04 on Monday. The business’s fifty day simple moving average is $6.21 and its 200-day simple moving average is $8.55. The firm has a market cap of $1.23 billion, a PE ratio of -2.71 and a beta of 0.53. Iovance Biotherapeutics has a 52 week low of $3.62 and a 52 week high of $18.24.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.26). The company had revenue of $73.69 million for the quarter, compared to analyst estimates of $72.17 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%.

Institutional Investors Weigh In On Iovance Biotherapeutics

Institutional investors have recently made changes to their positions in the stock. AlphaQuest LLC lifted its stake in shares of Iovance Biotherapeutics by 63.6% in the fourth quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 1,794 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at approximately $36,000. GF Fund Management CO. LTD. purchased a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $47,000. One68 Global Capital LLC acquired a new stake in shares of Iovance Biotherapeutics in the 4th quarter worth approximately $74,000. Finally, Quarry LP purchased a new position in Iovance Biotherapeutics in the 4th quarter valued at approximately $74,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.